| International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants |
45 |
| Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study |
40 |
| Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE) |
38 |
| Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study |
34 |
| Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review |
34 |
| Neutrophil Extracellular Traps Participate in All Different Types of Thrombotic and Haemorrhagic Complications of Coronary Atherosclerosis |
29 |
| Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays |
29 |
| Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study |
26 |
| The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases |
23 |
| Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors |
23 |
| Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study |
23 |
| Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry |
21 |
| Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs |
21 |
| Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference: October 6th and 7th, 2017 Rome, Italy |
21 |
| Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study |
20 |
| Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 000 Patients with Atrial Fibrillation |
20 |
| Dynamic Changes of CHA(2)DS(2)-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study |
19 |
| Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis |
17 |
| The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal |
16 |
| Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 582 Procedures |
15 |
| Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques |
15 |
| ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome |
15 |
| PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention |
14 |
| Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis |
14 |
| Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA(2)DS(2)-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients |
14 |
| Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A |
14 |
| Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis |
14 |
| Third-Generation P2Y(12) Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study |
12 |
| Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review |
12 |
| METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial |
12 |
| Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy |
12 |
| Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial |
12 |
| Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study |
11 |
| Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity |
11 |
| Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry |
11 |
| Platelet-Neutrophil Crosstalk in Atherothrombosis |
10 |
| Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? |
10 |
| Mutational Epidemiology of Congenital Fibrinogen Disorders |
10 |
| Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention |
10 |
| Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation |
10 |
| Changes in Oral Anticoagulation Therapy over One Year in 000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study |
10 |
| Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation |
10 |
| PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design |
10 |
| Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence |
10 |
| Apolipoprotein M Protects Lipopolysaccharide-Treated Mice from Death and Organ Injury |
10 |
| Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response |
9 |
| Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial |
9 |
| Gamma-Glutamyl Transferase-to-Platelet Ratio as a Novel Predictor of Long-Term Adverse Outcomes in Patients after Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study |
9 |
| Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease |
9 |
| Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients |
9 |
